Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

被引：188

作者：

Beasley, B. Nhi ^{[1
]}

Unger, Ellis F. ^{[2
]}

Temple, Robert ^{[2
]}

机构：

[1] US FDA, Div Cardiovasc & Renal Prod, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[2] US FDA, Off Drug Evaluat 1, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 19期

关键词：

ATRIAL-FIBRILLATION; WARFARIN;

D O I：

10.1056/NEJMp1103050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1788 / 1790

页数：3

共 6 条

[1]

[Anonymous], 2010, GUIDANCE IND NONINFE

[2] Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation [J].

Birman-Deych, E ;

Radford, MJ ;

Nilasena, DS ;

Gage, BF .

STROKE, 2006, 37 (04) :1070-1074

[3]

Connolly SJ, 2010, NEW ENGL J MED, V363, P1877

[4] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[5]

FDA, FDA APPR DRUG PROD

[6]

*FOOD DRUG ADM CTR, DAB PROP IND PREV ST

← 1 →